SINTX Technologies (SINT) Q2 2025 earnings summary

Executive summary

• Focus shifted to biomedical sector, prioritizing silicon nitride-based medical devices and divesting non-core assets, including the sale of TA&T and ceasing armor plant operations.

• Submitted 510(k) to FDA for silicon nitride osteotomy wedges, entering the foot and ankle reconstruction market.

• Workforce reduction and operational streamlining implemented to improve efficiency and reduce costs.

Financial highlights

• Total revenue for Q2 2025 was $0.15M, down 82% year-over-year; six-month revenue was $0.52M, down 66%.

• Net loss for Q2 2025 was $2.3M, compared to $2.2M in Q2 2024; six-month net loss was $4.6M, up from $3.1M year-over-year.

• Gross profit for Q2 2025 was $0.06M, down 85% year-over-year; six-month gross profit was $0.18M, down 84%.

• Cash and cash equivalents at June 30, 2025, were $4.3M, up from $3.6M at year-end 2024.

• Accumulated deficit reached $286M as of June 30, 2025.

Outlook and guidance

• Management expresses substantial doubt about the ability to continue as a going concern for the next 12 months without additional funding.

• Strategic focus on commercializing proprietary biomedical devices expected to drive future growth.

• Actively seeking additional equity and/or debt financing; current resources insufficient for all planned product development.